The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 346:1631-1636 May 23, 2002 Number 21
NextNext

Salmeterol for the Prevention of High-Altitude Pulmonary Edema
Claudio Sartori, M.D., Yves Allemann, M.D., Hervé Duplain, M.D., Mattia Lepori, M.D., Marc Egli, M.D., Ernst Lipp, M.D., Damian Hutter, M.D., Pierre Turini, M.D., Olivier Hugli, M.D., Stéphane Cook, M.D., Pascal Nicod, M.D., and Urs Scherrer, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Perspective
 by Voelkel, N. F.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Pulmonary edema results from a persistent imbalance between forces that drive water into the air space and the physiologic mechanisms that remove it. Among the latter, the absorption of liquid driven by active alveolar transepithelial sodium transport has an important role; a defect of this mechanism may predispose patients to pulmonary edema. Beta-adrenergic agonists up-regulate the clearance of alveolar fluid and attenuate pulmonary edema in animal models.

Methods In a double-blind, randomized, placebo-controlled study, we assessed the effects of prophylactic inhalation of the beta-adrenergic agonist salmeterol on the incidence of pulmonary edema during exposure to high altitudes (4559 m, reached in less than 22 hours) in 37 subjects who were susceptible to high-altitude pulmonary edema. We also measured the nasal transepithelial potential difference, a marker of the transepithelial sodium and water transport in the distal airways, in 33 mountaineers who were prone to high-altitude pulmonary edema and 33 mountaineers who were resistant to this condition.

Results Prophylactic inhalation of salmeterol decreased the incidence of high-altitude pulmonary edema in susceptible subjects by more than 50 percent, from 74 percent with placebo to 33 percent (P=0.02). The nasal potential-difference value under low-altitude conditions was more than 30 percent lower in the subjects who were susceptible to high-altitude pulmonary edema than in those who were not susceptible (P<0.001).

Conclusions Prophylactic inhalation of a beta-adrenergic agonist reduces the risk of high-altitude pulmonary edema. Sodium-dependent absorption of liquid from the airways may be defective in patients who are susceptible to high-altitude pulmonary edema. These findings support the concept that sodium-driven clearance of alveolar fluid may have a pathogenic role in pulmonary edema in humans and therefore represent an appropriate target for therapy.


Source Information

From the Department of Internal Medicine (C.S., H.D., M.L., M.E., P.T., O.H., S.C., P.N., U.S.) and the Botnar Center for Clinical Research (C.S., H.D., M.L., M.E., P.T., O.H., S.C., U.S.), Centre Hospitalier Universitaire Vaudois, Lausanne; and the Swiss Cardiovascular Center, University Hospital, Bern (Y.A., E.L., D.H.) — both in Switzerland.

Address reprint requests to Dr. Scherrer at the Department of Internal Medicine, BH 10.642, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland, or at urs.scherrer{at}chuv.hospvd.ch.

Full Text of this Article


Related Letters:

Salmeterol for the Prevention of High-Altitude Pulmonary Edema
Cruden N. L.M., Newby D. E., Webb D. J., Bärtsch P., Mairbäurl H., Basnyat B., Prodhan P., Noviski N. N., Kinane T. B., Swenson E. R., Maggiorini M., Scherrer U., Sartori C., Allemann Y.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:1282-1285, Oct 17, 2002. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.